Preliminary exploration of dynamic changes in circulating mitochondrial DNA (ΔmtDNA) as a prognostic biomarker for acute ST-segment elevation myocardial infarction patients: a prospective observational study
Circulating mitochondrial DNA released during heart attacks predicts future heart problems, though further study is needed before clinical implementation.
In 236 STEMI patients, rising peri-procedural circulating mitochondrial DNA (ΔmtDNA) independently predicted 1-year MACE risk with a dose-response relationship, though the association was driven primarily by recurrent angina rather than hard endpoints like death or MI. ΔmtDNA represents a novel biomarker of myocardial ischemia-reperfusion injury requiring formal discrimination analysis and comparison with established risk scores before clinical use.
What the study was
- Study design
- Prospective cohort study with biomarker measurement
- Population
- 236 STEMI patients undergoing emergency PCI; 1-year follow-up for MACE
- Sample size
- 236
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- BMC Cardiovasc Disord
Why it surfaced
Novel peri-procedural liquid biopsy biomarker in STEMI; prospective design with 1-year follow-up. Limitation: MACE mostly recurrent angina, not hard endpoints. Single-centre, no AUC/discrimination reported.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.